Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety and Tolerability Study of GB301 Given as a Single Intravenous Dose in Subjects With Mild to Moderate Alzheimer's Disease

NCT03865017 is registered in ClinicalTrials.gov with VTBIO Co. LTD as lead sponsor.

NCT NCT03865017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03865017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety and Tolerability Study of GB301 Given as a Single Intravenous Dose in Subjects With Mild to Moderate Alzheimer's Disease
Lead sponsor
VTBIO Co. LTD
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 1, 2019
Completion date
December 1, 2021
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease